Attaya Suvannasankha, MD
Hematology & Oncology · Indianapolis, INNPI 1760447643
Payments from drug & device makers
Across 629 payments — averaging $13,116 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5.3M
- GSK$1.3M
- Janssen Research & Development, LLC$670K
- Pfizer$485K
- E.r. Squibb & Sons, L.L.C.$269K
- Bristol Myers Squibb$36K
- plus $122K from 10 others
Across 54 payments — averaging $1207.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$44K
- Regeneron$15K
- Karyopharm Therapeutics Inc.$5K
- Pfizer$1K
- GSK$186
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 195 | $5,339,148 |
| GSK | 230 | $1,329,516 |
| Janssen Research & Development, LLC | 93 | $669,956 |
| Pfizer | 15 | $485,001 |
| E.r. Squibb & Sons, L.L.C. | 23 | $268,687 |
| Bristol Myers Squibb | 3 | $35,714 |
| AstraZeneca | 1 | $34,582 |
| Sanofi US Services Inc. | 1 | $30,222 |
| Johnson & Johnson(2 entities) | 28 | $16,257 |
| Sanofi | 12 | $15,218 |
| Karyopharm Therapeutics Inc. | 11 | $12,219 |
| Janssen Global Services, LLC | 4 | $6,021 |
| Janssen Scientific Affairs, LLC | 4 | $4,915 |
| Legend Biotech USA Inc. | 3 | $1,649 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $539 |
| Genentech, Inc. | 1 | $150 |
How this compares
$8,249,794 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Indianapolis
- Gregory DurmIndianapolis$22.7M
- Nabil AdraIndianapolis$13.2M
- Shadia JalalIndianapolis$4.6M
- Ruemu BirhirayIndianapolis$4M
- Richard GaynorIndianapolis$3.7M
- Anand TandraIndianapolis$2.2M
- Brian MulherinIndianapolis$2.2M
- Kathy MillerIndianapolis$1.9M
- Anita TurkIndianapolis$1.5M
- Safi ShahdaIndianapolis$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.